Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Sarcoma × Adjuvants, Pharmaceutic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 Carcinoma, Hepatocellular 2 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Squamous Intraepithelial Lesions 1 Skin Neoplasms 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Rectal Neoplasms 1 Prostate Adenocarcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Papillomavirus Infections 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Liver Diseases 1 Liposarcoma 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Head and Neck Neoplasms 1 Breast Neoplasms 1

Interventions

Doxorubicin 126 Ifosfamide 76 Radiotherapy 71 Cyclophosphamide 64 Gemcitabine 54 Filgrastim 48 pazopanib 37 pembrolizumab 36 Etoposide 36 Docetaxel 35 Vincristine 34 Trabectedin 31 Cisplatin 30 Nivolumab 29 Irinotecan 23 Magnetic Resonance Spectroscopy 22 Carboplatin 22 Temozolomide 20 Ipilimumab 20 Radiation 17 Mesna 17 Granulocyte Colony-Stimulating Factor 17 Bevacizumab 17 Sirolimus 16 Melphalan 16 Biopsy 16 Specimen Handling 15 Dactinomycin 15 eribulin 14 anlotinib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06116578 2025-12-01

NeoSarc

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡